Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models
Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models
复制标题
间充质干细胞/基质细胞治疗小动物模型肾功能受损的系统评价和荟萃分析
DOI：
10.1111/nep.12018
复制
发表时间：
2013-03-01
期刊：
影响因子：
2.5
通讯作者：
Zhao, Weihong
中科院分区：
文献类型：
--
作者：
Wang, Yan;He, Juan;Zhao, Weihong
目的对近年来间充质干/基质细胞（MSC）治疗肾损伤的小动物实验进行Meta分析，为设计大型动物实验和人体临床试验提供重要线索。方法对21篇文献进行分析。这些数据来自PubMed和Embase数据库。所有数据用RevMan 5.1和SPSS17.0进行统计分析。采用随机效应模型进行汇总分析和多元荟萃回归分析。还探讨了研究中的异质性和发表偏倚。结果骨髓间充质干细胞治疗后，肾功能衰竭动物模型的血清肌酐（Scr）升高。探索性多元回归分析显示，影响骨髓间充质干细胞血肌酐下降的主要因素为血肌酐测定时间点（早期测定较晚期下降更明显（P=0.005））和骨髓间充质干细胞移植途径（动脉移植较肾内移植和静脉注射下降更明显（P=0.040））。亚组分析显示，随着MSC数量的增加（>106），肾缺血-再灌注损伤（IRI）模型，以及损伤后晚给药（>1天），Scr下降趋势更大。结论本荟萃分析证实MSC治疗可改善肾功能损害。骨髓间充质干细胞经动脉灌注后对早期肾损伤有明显的治疗作用。此外，这种荟萃分析可能为MSC研究中的动物实验甚至人类临床试验提供重要线索。
Aim The meta-analysis of recent small animal experiments of mesenchymal stem/stromal cells (MSC) therapy for impaired kidney could provide significant clues to design large animal experiments as well as human clinical trials. Method A total of 21 studies was analyzed. These, were indexed from PubMed and Embase databases. All data were analyzed by RevMan 5.1 and SPSS 17.0. Pooled analysis and multivariable meta-regression were calculated by random effects models. Heterogeneity and publication bias across the studies were also explored. Results Pooled analysis showed elevated serum creatinine (Scr) reduction in the animal models of renal failure following MSC therapy. By exploratory multivariable meta-regression, significant influence factors of Scr reduction were the time point of Scr measurement (early measurement showed greater reduction than the late (P=0.005)) and the route of MSC delivery (arterial delivery of MSCs caused greater reduction in elevated Scr, when compared with the intra-renal delivery and intravenous injection (P=0.040)). Subgroup analysis showed there tended to be greater reduction in Scr with higher MSC number (>106), the renal ischemia-reperfusion injury (IRI) model, and late administration (>1 day) after injury. Conclusion The present meta-analysis confirmed that MSC therapy could improve impaired renal function. MSCs might get obvious effect in the early stage of renal injuries after arterial delivery. Further, this meta-analysis may provide important clues for animal experiments even for human clinical trials in MSC studies.